Global Information
회사소개 | 문의 | 비교리스트

제네릭 의약품 시장 예측(2020-2026년)

Generic Drugs Market 2020-2026

리서치사 Orion Market Research Pvt Ltd
발행일 2021년 05월 상품코드 1025225
페이지 정보 영문 배송안내 2-3일 (영업일 기준)
가격
US $ 5,125 ₩ 7,409,000 Unprintable PDF (Single User License)
US $ 6,625 ₩ 9,578,000 Unprintable PDF (5 User License)
US $ 8,280 ₩ 11,971,000 Printable PDF (Corporate License)


제네릭 의약품 시장 예측(2020-2026년) Generic Drugs Market 2020-2026
발행일 : 2021년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 제네릭 의약품 시장 규모는 예측 기간 동안 상당한 CAGR로 확대 될 것으로 전망되고 있습니다. 시장 성장을 가속화시키는 주요 요인으로 만성 질환의 이환율 증가와 제네릭 의약품의 큰 비용 효과를 들수 있습니다. 암, CVD, 당뇨병 등 만성 질환 이환율 증가는 시장 성장을 촉진하고 있습니다. 국제 당뇨병 연맹(IDF)에 따르면, 2019년에는 약 4억 6,300만명의 성인(20-79세)이 당뇨병을 앓고 있습니다. 2045년에는 7억명에 이를 것으로 예상되고 있습니다. 당뇨병 브랜드약 중 제네릭 의약품 증가는 환자의 비용 부담을 경감하는데 이어져, 시장 성장을 촉진하고 있습니다.

세계의 제네릭 의약품(Generic Drugs) 시장에 대해 조사 분석 했으며, 시장 개요/시장 결정 요인/시장 세분/경쟁 상황/지역별 분석/주요 기업 등에 대해 체계적인 정보를 제공하고 있습니다.

목차

제1장 보고서의 개요

제2장 시장 개요와 통찰력

  • 조사 범위
  • 애널리스트의 통찰력과 현재 시장 동향
  • 규칙과 규제

제3장 경쟁 상황

  • 기업 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Lupin Ltd.
    • Novartis International AG
    • Sun Pharmaceutical Industries Ltd.

제4장 시장의 결정 요인

  • 성장 요인
  • 억제 요인
  • 시장 기회

제5장 시장 세분화

  • 애플리케이션별 세계 제네릭 의약품 시장
    • CVD
    • 근골격계 질환
    • 감염
    • 신경
    • 당뇨병
    • 기타
  • 투여 경로별 세계 제네릭 의약품 시장
    • 경구
    • 국소
    • 주사 가능
    • 흡입기

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타 유럽
  • 아시아 태평양 지역
    • 중국
    • 인도
    • 일본
    • 기타 아시아 태평양 지역
  • 기타 지역

제7장 기업 개요

  • Abbott Laboratories
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Ltd.
  • Baxter International Inc.
  • Cipla Ltd.
  • Dr. Reddy 's Laboratories Ltd.
  • Eli Lilly and Co.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Lannett Co. Inc.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis International AG
  • Novo Nordisk A/S
  • Stada Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
LYJ 21.09.10

LIST OF TABLES

  • 1. GLOBAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 2. GLOBAL GENERIC DRUGS IN CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL GENERIC DRUGS IN CVD MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL GENERIC DRUGS IN MUSCULOSKELETAL MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL GENERIC DRUGS IN INFECTIOUS DISEASESMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL GENERIC DRUGS IN NEUROLOGYMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL GENERIC DRUGS IN DIABETES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL GENERIC DRUGS IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
  • 10. GLOBAL ORAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL TOPICAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 12. GLOBAL INJECTABLE GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 13. GLOBAL INHALABLE GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 14. GLOBAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 15. NORTH AMERICAN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 16. NORTH AMERICAN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 17. NORTH AMERICAN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
  • 18. EUROPEAN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 19. EUROPEAN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 20. EUROPEAN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
  • 21. ASIA-PACIFIC GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 22. ASIA-PACIFIC GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 23. ASIA-PACIFIC GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
  • 24. REST OF THE WORLD GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 25. REST OF THE WORLD GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 2. GLOBAL GENERIC DRUGS MARKET SHARE BY ROUTE OF ADMINISTRATION, 2019 VS 2026 (%)
  • 3. GLOBAL GENERIC DRUGS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)

Global Generic Drugs Market Size, Share & Trends Analysis Report, By Application (Cancer, CVD, Musculoskeletal Diseases, Infectious Diseases, Neurology, Diabetes, and Others), By Route of Administration (Oral, Topical, Injectable, and Inhaler) and Forecast, 2020-2026

The global generic drugs market is estimated to grow at a significant CAGR during the forecast period. Some pivotal factors accelerating market growth include the rising prevalence of chronic diseases and the cost-effectiveness of generic drugs. A significant rise in the incidences of chronic diseases such as cancer, CVD, and diabetes is driving market growth. As per the International Diabetes Federation (IDF), in 2019, nearly 463 million adults (20-79 years) were suffering from diabetes. It is expected to reach 700 million by 2045. 

This leads to an increasing demand for generic medicines for diabetes which includes Glyburide, Tolazamide (Tolinase), Acetohexamide, Glimepiride (Amaryl), and Glipizide. Additionally, several generic equivalents of the drug metformin (earlier sold only as Glucophage XR or Glucophage) are now available. The combinations of metformin and glipizide (Metaglip) and metformin and glyburide (Glucovance) are available as generic drugs. The increasing availability of generic versions of branded diabetes drugs is supporting to reduce the cost burden on patients, which, in turn, is driving the market growth. 

Geographically, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (Row). In 2019, North America held the largest share in the market owing to the US FDA initiatives to increase the availability of generic medicines in the market. For instance, in October 2007, the US FDA introduced the Generic Initiative for Value and Efficiency (GIVE). As an initiative, GIVE will utilize existing resources to support the US FDA to advance and streamline the approval process of generic drugs. The initiative is intended to increase the availability of generic drugs. The increasing availability of generic-drug alternatives results in more cost-savings to consumers, as generic drugs cost nearly 30% to 80% lower compared to the brand name drugs.

Some key players in the market include Mylan N.V., Teva Pharmaceutical Industries Ltd., Lupin Ltd., Novartis International AG, and Sun Pharmaceutical Industries Ltd. The market players are using some key strategies to increase their market share. For instance, in September 2020, Sun Pharmaceutical Industries Ltd. declared the launch of ILUMYA (tildrakizumab) Subcutaneous Injection 100 mg Syringe in Japan to treat adult patients suffering from plaque psoriasis who have an insufficient response to traditional therapies. ILUMYA is a humanized lgG1/k monoclonal antibody that is intended to selectively attach to the p19 subunit of IL23 and stops its interaction with the IL-23 receptor. This leads to an inhibition of the release of chemokines and proinflammatory cytokines. 

Research Methodology

The market study of the global generic drugs market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

Financial reports of companies involved in the market.

Whitepapers, research-papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Generic Drugs Market Research and Analysis by Application

Global Generic Drugs Market Research and Analysis by Route of Administration

The Report Covers

Comprehensive research methodology of the global generic drugs market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global generic drugs market.

Insights about market determinants which are stimulating the global generic drugs market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Mylan N.V.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Teva Pharmaceutical Industries Ltd.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Lupin Ltd.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Novartis International AG
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Sun Pharmaceutical Industries Ltd.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Generic Drugs Market by Application
    • 5.1.1. Cancer
    • 5.1.2. CVD
    • 5.1.3. Musculoskeletal Diseases
    • 5.1.4. Infectious Diseases
    • 5.1.5. Neurology
    • 5.1.6. Diabetes
    • 5.1.7. Others
  • 5.2. Global Generic Drugs Market by Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Topical
    • 5.2.3. Injectable
    • 5.2.4. Inhaler

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Amneal Pharmaceuticals LLC
  • 7.3. Aurobindo Pharma Ltd.
  • 7.4. Baxter International Inc.
  • 7.5. Cipla Ltd.
  • 7.6. Dr. Reddy's Laboratories Ltd.
  • 7.7. Eli Lilly and Co.
  • 7.8. Fresenius SE & Co. KGaA
  • 7.9. GlaxoSmithKline plc
  • 7.10. Glenmark Pharmaceuticals Ltd.
  • 7.11. Hikma Pharmaceuticals PLC
  • 7.12. Lannett Co. Inc.
  • 7.13. Lupin Ltd.
  • 7.14. Merck & Co., Inc.
  • 7.15. Mylan N.V.
  • 7.16. Novartis International AG
  • 7.17. Novo Nordisk A/S
  • 7.18. Stada Arzneimittel AG
  • 7.19. Sun Pharmaceutical Industries Ltd.
  • 7.20. Teva Pharmaceutical Industries Ltd.
Back to Top
전화 문의
F A Q